Modulation of the Angiotensin II–HIF-1α-HILPDA Axis: Implications for Ferroptosis and Radioresistance in Nasopharyngeal Carcinoma

Study Background and Research Question

Nasopharyngeal carcinoma (NPC) is a malignancy with a distinct epidemiological distribution, notably prevalent in East and Southeast Asia. Radiotherapy remains the standard treatment due to the tumor's anatomical inaccessibility; however, up to 20% of patients experience disease recurrence or persistence, largely attributed to cellular radioresistance. While prior research has implicated the renin-angiotensin system (RAS), and particularly local production of angiotensin II (Ang II), in promoting tumor progression and modulating therapeutic response, the molecular underpinnings by which Ang II influences NPC radioresistance have not been fully elucidated. The reference study (Chen et al., 2025) addresses this knowledge gap by dissecting the regulatory interactions between Ang II, ferroptosis, and the hypoxia-inducible factor (HIF)-1α–HILPDA axis in NPC.

Key Innovation from the Reference Study

The central innovation of the study lies in its identification of a localized Ang II–driven positive feedback loop that enhances NPC radioresistance by suppressing ferroptosis. Specifically, the research demonstrates that Ang II stabilizes HIF-1α via MAPK pathway activation and through direct interaction with angiotensinogen (AGT), which binds to HIF-1α and prevents its degradation. This stabilization upregulates HILPDA, a lipid droplet-associated protein, ultimately reducing susceptibility to ferroptotic cell death under radiotherapeutic stress. This mechanistic insight provides a concrete molecular rationale for targeting the Ang II–HIF-1α–HILPDA axis to improve radiosensitivity in resistant NPC.

Methods and Experimental Design Insights

To model acquired radioresistance, radioresistant NPC cell lines (HONE1-RR and SUNE1-RR) were established. The study employed a combination of quantitative RT-PCR, western blotting, and ELISA to quantify AGT and Ang II activity, and used transmission electron microscopy, ferrous ion detection, and lipid peroxidation assays to assess ferroptosis. The downstream signaling mechanisms were interrogated using bioinformatics, co-immunoprecipitation, and dual-luciferase reporter assays. Functional implications were validated via colony formation and Cell Counting Kit-8 (CCK8) assays, as well as by evaluating tumor growth and radiosensitivity in a nude mouse xenograft model. Immunohistochemistry was performed on clinical NPC specimens to correlate AGT, HIF-1α, HILPDA, and GPX4 expression with patient outcomes.

Protocol Parameters

• Cell culture: NPC cells cultured in hypoxic conditions (1% O₂) to model the tumor microenvironment.
• Radioresistant line establishment: Fractionated irradiation to induce radioresistance in parental NPC lines.
• Ferroptosis assessment: Measurement of lipid ROS, ferrous ion accumulation, and mitochondrial morphology by TEM.
• Pathway analysis: Bioinformatics-guided identification of HIF-1α/HILPDA as downstream targets; confirmed by reporter and immunoprecipitation assays.
• In vivo validation: NPC xenografts in nude mice subjected to radiotherapy, with or without Ang II modulation and ferroptosis inducers.

Core Findings and Why They Matter

The study provides several lines of evidence that local Ang II is a key determinant of radioresistance in NPC by actively suppressing ferroptosis:

• Radioresistant NPC cells exhibited elevated AGT and Ang II levels, which correlated with increased expression of HIF-1α and HILPDA, and decreased ferroptotic markers.
• Mechanistically, Ang II stabilized HIF-1α via both MAPK pathway activation and AGT-mediated protection from degradation. This dual regulation augmented HILPDA expression, fostering lipid droplet accumulation and further inhibiting ferroptosis.
• Blocking Ang II signaling (using ARBs) or pharmacologically inducing ferroptosis restored radiosensitivity in vitro and in NPC xenograft models.
• Immunohistochemical analysis of NPC patient samples revealed that high AGT/HIF-1α/HILPDA expression was predictive of poor radiosensitivity and prognosis.

These findings define a new axis of therapeutic vulnerability in NPC, substantiating the rationale for dual targeting of Ang II signaling and ferroptosis pathways to overcome resistance to radiotherapy. As discussed in the internal article "Angiotensin II Suppresses Ferroptosis to Drive NPC Radioresistance", such molecular dissection provides actionable targets for radiosensitization in resistant NPC phenotypes.

Comparison with Existing Internal Articles

Prior internal resources, such as "SCH772984: Redefining ERK1/2 Inhibition for Tumor Radiosensitivity", have discussed the use of potent ERK1/2 inhibitors to disrupt MAPK/ERK-driven radioresistance in various tumor models, including those with BRAF, NRAS, and KRAS mutations. Although the reference study focused on endogenous Ang II–MAPK–HIF-1α signaling rather than direct ERK inhibition, the mechanistic link between Ang II and MAPK pathway activation underscores the translational relevance of ERK1/2 inhibitors in modulating radiosensitivity. The review "SCH772984: Precision ERK1/2 Inhibition for Translational Cancer Research" further details how selective ERK pathway inhibition can optimize radiosensitization protocols, aligning with the current study's rationale for targeting MAPK signaling in resistant NPC.

Limitations and Transferability

While the study presents a compelling mechanistic framework and robust preclinical evidence, several limitations warrant consideration. First, although in vivo NPC xenograft models provide proof of concept, the tumor microenvironmental complexity in patients may introduce additional regulatory layers not fully recapitulated in animal models. Second, the specific crosstalk between MAPK/ERK inhibition and Ang II-HIF-1α–mediated lipid metabolism in NPC remains to be systematically explored using selective pharmacological probes. Finally, translation to clinical protocols will require careful validation of predictive biomarkers (AGT, HIF-1α, HILPDA, GPX4) and rigorous assessment of safety and efficacy for dual-pathway targeting strategies.

Research Support Resources

For investigators seeking to model MAPK/ERK pathway inhibition in the context of radioresistant tumors, highly selective ERK1/2 inhibitors such as SCH772984 (SKU A3805, APExBIO) offer nanomolar potency and robust selectivity, enabling precise dissection of MAPK/ERK-driven signaling in cell-based and in vivo assays. According to the product information, SCH772984 is particularly effective in models harboring BRAF, NRAS, or KRAS mutations and can be combined with other experimental modulators to interrogate radiosensitization workflows. When designing experiments informed by the Ang II–MAPK–HIF-1α axis, researchers can consider integrating SCH772984 to probe the contribution of ERK1/2 activity to ferroptosis and radioresistance, as suggested by the mechanistic links highlighted in both the reference study and related internal resources.